Real world treatment patterns following the initiation of proprotein convertase subtilisin/kexin type 9 antibody inhibitors among adults in the United States, 2015-2019.

Challenge

Real-world prescribing patterns following PCSK9 inhibitor initiation had not been characterized in a large US patient population, leaving gaps in understanding how these therapies are used in clinical practice.

Solution

Target RWE researchers analyzed real-world treatment patterns following PCSK9 inhibitor initiation, characterizing rates and predictors of continuation, dose change, switching, and augmentation across commercially insured US patients.